GLUE — Monte Rosa Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1826457 ·
Last close
$9.07
Market Cap
$775.03M
52W High
$25.77
52W Low
$8.83
ADV30
1,459,282
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 54,366,000 — -1,939,000 3,063,000 697,725,000 45,180,000 201,517,000
Jun 2026 8,968,000 — -49,130,000 -43,397,000 691,161,000 90,104,000 203,880,000
Mar 2026 4,210,000 — -50,034,000 -44,503,000 736,428,000 159,859,000 214,512,000
Dec 2025 2,781,000 — -49,715,000 -46,135,000 448,659,000 129,883,000 215,603,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-165,475,000
Investing CF
$-359,458,000
Financing CF
$361,738,000
CapEx
$-8,916,000
Dividends Paid
—
Buybacks
$-357,000
EPS Diluted TTM
$-1.70
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-562,051,000
Inventory
—
Receivables
$57,624,000
ST Investments
$532,546,000
EBIT TTM
$-150,818,000
Pretax Income TTM
$-129,937,000
Interest Exp TTM
—
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$28,727,000
EBITDA
$-173,728,000
Free Cash Flow
$-74,449,752
Enterprise Value
$339,973,984
Total Cash
$621,104,000
Total Debt
$37,987,000
Shares Out
85,450,119
Trailing EPS
$-1.39
Book Value
$3.56
ROE
-42.7%
ROA
-21.6%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 123,672,000 -54,208,000 -38,626,000 448,659,000 215,603,000 233,056,000 -22,798,000
Dec 2024 75,622,000 -81,112,000 -72,700,000 438,732,000 215,796,000 222,936,000 41,996,000
Dec 2023 0 -143,311,000 -135,352,000 303,755,000 124,505,000 179,250,000 -43,802,000
Dec 2022 0 -112,384,000 -108,501,000 342,389,000 70,976,000 271,413,000 -92,466,000

TTM Snapshot

Revenues TTM
$28,727,000
NetIncome TTM
$-161,116,000
OpCashFlow TTM
—
Assets (Latest)
$691,161,000
Forward EPS
$-1.81

Max Pain — expiry 2027-04-16

max pain strike: $12.50 · spot: $9.07 · call oi: 2,079 · put oi: 1,810
Expected Move to 2027-04-16: ±$5.38 (59.26%) — implied range $3.69 – $14.44 · ATM straddle on $10.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
AURA Aura Biosciences, Inc. $744.13M $7.15 —
MGTX MeiraGTx Holdings plc $826.80M $8.46 —
BBTX Bambusa Therapeutics, Inc. $832.91M $16.35 —
PRME Prime Medicine, Inc. $854.20M $3.84 —
SLDB Solid Biosciences Inc. $695.33M $6.23 —

News headlines (Yahoo Finance, 1h cache)

Monte Rosa Therapeutics (GLUE) Stock Fair Value Edges Lower As Analysts Weigh NEK7 Promise And Risk
2026-11-11 04:32 · Yahoo
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout
2026-11-09 12:00 · Yahoo
Monte Rosa Therapeutics (GLUE) Tops Q3 Earnings and Revenue Estimates
2026-11-05 13:35 · Yahoo
Monte Rosa Therapeutics: Q3 Earnings Snapshot
2026-11-05 12:58 · Yahoo
Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
2026-11-05 12:00 · Yahoo
Wall Street Analysts See a 152.87% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?
2026-11-03 13:55 · Yahoo
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
2026-11-02 12:00 · Yahoo
Monte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
2026-10-29 13:00 · Yahoo
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
2026-10-28 11:00 · Yahoo
Are Options Traders Betting on a Big Move in Monte Rosa Therapeutics Stock?
2026-10-23 10:51 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.